MarketCap
Facebook
X
TelegramEyeGate Pharmaceuticals, Inc. Langfristige Verbindlichkeiten 2011-2026 | EYEG
Langfristige Verbindlichkeiten Jährlich EyeGate Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 6.39 M | 2.08 M | 1.48 M | 1.4 M | 2.75 M | - | 36.4 M | 36.4 M | 36.4 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 36.4 M | 1.4 M | 15.4 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
4.4 M | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 219.83 | -0.92 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
7.22 B | $ 7.69 | 1.39 % | $ 6.83 B |  Spain |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.28 M | $ 0.6 | -2.83 % | $ 6.87 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
277 M | $ 13.01 | 2.12 % | $ 784 M | USA |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 0.8 | 2.29 % | $ 133 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | USA |
 |
Incyte Corporation
INCY
|
315 M | $ 91.13 | 0.38 % | $ 17.8 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | USA |
 |
Inovio Pharmaceuticals
INO
|
107 M | $ 1.6 | 0.95 % | $ 35.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
113 M | $ 21.15 | 4.86 % | $ 3.48 B | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Inventiva S.A.
IVA
|
13.8 M | $ 6.07 | 5.02 % | $ 138 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.3 | 1.3 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
1.06 M | - | -5.98 % | $ 34.1 M | USA |
 |
Decibel Therapeutics
DBTX
|
523 K | - | - | $ 123 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
15.9 M | - | - | $ 2.18 B | USA |
 |
Cardiff Oncology
CRDF
|
451 K | $ 1.8 | 0.08 % | $ 120 M | USA |